Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 10, 2026

Pentagon Moves to Secure Rare Earth Metals for Next-Gen Weapons

View original at finance.yahoo.com
Pentagon Moves to Secure Rare Earth Metals for Next-Gen Weapons OilPrice.com Market Commentary NEW YORK, March 10, 2026 /PRNewswire/ -- The Pentagon has taken a step toward rebuilding one of the most fragile links in the U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rare earth elements are relatively widespread geologically; what is scarce is the industrial capability to economically separate them into high-purity oxides and then convert them into metals and alloys at scale

    80% confidence
  • Defense customers need consistency in rare earth metal production to exact specifications

    80% confidence
  • REalloys has already delivered specialty metals and alloys under U.S. government contracts at its Euclid, Ohio facility

    80% confidence
  • Policy timing adds pressure as moving from project to commercial heavy rare earth metallization can take multiple years

    80% confidence
  • If China stopped supplying rare earths, it would mean no F-35s and no missiles for the U.S.

    80% confidence
  • REalloys' modular design allows reactors to be deployed and replicated more quickly than conventional facilities while reducing both capital intensity and operating costs

    80% confidence
  • Metallization is one of the least developed parts of the rare earth value chain outside China, requiring multi-year timeline to build capability even with strong execution and capital

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Pentagon Moves to Secure Rare Earth Metals for Next-Gen Weapons — Source | Via News | ViaNews Market